1. Academic Validation
  2. Label-free, real-time monitoring of cytochrome C drug responses in microdissected tumor biopsies with a multi-well aptasensor platform

Label-free, real-time monitoring of cytochrome C drug responses in microdissected tumor biopsies with a multi-well aptasensor platform

  • Sci Adv. 2024 Sep 6;10(36):eadn5875. doi: 10.1126/sciadv.adn5875.
Tran N H Nguyen 1 Lisa F Horowitz 1 Timothy Krilov 1 Ethan Lockhart 1 Heidi L Kenerson 2 Taranjit S Gujral 3 Raymond S Yeung 2 Netzahualcóyotl Arroyo-Currás 4 Albert Folch 1
Affiliations

Affiliations

  • 1 Department of Bioengineering, University of Washington, Seattle, WA 98105, USA.
  • 2 Department of Surgery, University of Washington, Seattle, WA 98105, USA.
  • 3 Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98105, USA.
  • 4 Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
Abstract

Functional assays on intact tumor biopsies can complement genomics-based approaches for precision oncology, drug testing, and organs-on-chips Cancer disease models by capturing key therapeutic response determinants, such as tissue architecture, tumor heterogeneity, and the tumor microenvironment. Most of these assays rely on fluorescent labeling, a semiquantitative method best suited for single-time-point assays or labor-intensive immunostaining analysis. Here, we report integrated aptamer electrochemical sensors for on-chip, real-time monitoring of cytochrome C, a cell death indicator, from intact microdissected tissues with high affinity and specificity. The platform features a multi-well sensor layout and a multiplexed electronic setup. The aptasensors measure increases in cytochrome C in the supernatant of mouse or human microdissected tumors after exposure to various drug treatments. Because of the sensor's high affinity, it primarily tracks rising concentrations of cytochrome C, capturing dynamic changes during Apoptosis. This approach could help develop more advanced Cancer disease models and apply to Other complex in vitro disease models, such as organs-on-chips and organoids.

Figures